Analytical Data
-
Gene name
NKG2D/CD314
- Application
-
Alternative Names
CD314; KLR-K1; KLR; NKG2-D; NKG2-D Type II Integral Membrane Protein; NK cell receptor D; NKG2-D-activating NK receptor
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P26718
-
Expression Region
Thr92~Val216
-
Molecular Weight
16kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NKG2D/CD314 is an important activating receptor expressed on the surface of natural killer (NK) cells and certain subsets of T cells, playing a crucial role in the immune response against tumors and viral infections. The receptor recognizes stress-induced molecules such as MICA, MICB, and ULBPs that are upregulated on the surface of transformed or infected cells, driving the activation of NK cells and leading to target cell lysis. Understanding the biology of NKG2D/CD314 and its ligands has significant implications for developing immunotherapeutic strategies aimed at enhancing anti-tumor immunity. Research has focused on engineering recombinant proteins based on NKG2D/CD314 to explore their potential in a variety of applications, including cancer immunotherapy and vaccine development. These recombinant proteins can serve as therapeutic agents that mimic the natural receptor's function, facilitating targeted killing of malignant cells. Furthermore, they offer opportunities for enhancing the recognition of tumor cells by immune effectors, potentially overcoming immune evasion mechanisms employed by cancer cells. As such, the study of NKG2D/CD314 recombinant proteins is vital for devising innovative treatments that leverage the body’s immune system to combat malignancies and improve patient outcomes.
